World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
74700
World Ranking
9451
National Ranking
4877

Overview

Michael A. Postow is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on oncology, molecular biology, and immunology, with substantial contributions to cancer immunotherapy and biomarkers, CAR-T cell therapy research, melanoma and MAPK pathways, cutaneous melanoma detection and management, immunotherapy and immune responses, cancer genomics and diagnostics, and colorectal cancer treatments and studies.

The scientist has authored numerous papers published in high-impact journals and venues. Their frequent publication venues include:

  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Cancer Research
  • Annals of Oncology

Some of their recent papers comprise the following:

  • "Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients," 2022, Cell
  • "Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors," 2021, Nature Communications
  • "Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade," 2021, Nature Medicine
  • "Neoadjuvant relatlimab and nivolumab in resectable melanoma," 2022, Nature
  • "Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma," 2024, New England Journal of Medicine

Their collaboration network includes frequent co-authors such as:

  • Margaret K. Callahan
  • Alexander N. Shoushtari
  • Katherine S. Panageas
  • Jedd D. Wolchok
  • James W. Smithy

Michael A. Postow's main fields of study encompass medicine and biochemistry, genetics and molecular biology. Within subfields, their work is particularly concentrated in oncology, molecular biology, immunology, pulmonary and respiratory medicine, and radiology, nuclear medicine and imaging.

Best Publications

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

    Alexandra Snyder;Vladimir Makarov;Taha Merghoub;Jianda Yuan

  • Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

    Michael A Postow;Robert Sidlow;Matthew D Hellmann

  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

    Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

  • Immune Checkpoint Blockade in Cancer Therapy

    Michael A. Postow;Margaret K. Callahan;Jedd D. Wolchok

  • Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

    Michael A. Postow;Margaret K. Callahan;Margaret K. Callahan;Christopher A. Barker;Christopher A. Barker;Yoshiya Yamada;Yoshiya Yamada

  • OncoKB: A Precision Oncology Knowledge Base.

    Debyani Chakravarty;Jianjiong Gao;Sarah Phillips;Ritika Kundra

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

    Alexander C. Huang;Michael A. Postow;Michael A. Postow;Robert J. Orlowski;Rosemarie Mick

  • Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

    J. Naidoo;D. B. Page;B. T. Li;L. C. Connell

  • Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

    Troy Z. Horvat;Nelly G. Adel;Thu-Oanh Dang;Parisa Momtaz

  • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

    Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid

  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    F Stephen Hodi;Jason Chesney;Anna C Pavlick;Caroline Robert

  • Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

    Jarushka Naidoo;Xuan Wang;Xuan Wang;Xuan Wang;Kaitlin M. Woo;Kaitlin M. Woo;Tunc Iyriboz;Tunc Iyriboz

  • Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.

    Claire F. Friedman;Claire F. Friedman;Tracy A. Proverbs-Singh;Tracy A. Proverbs-Singh;Michael A. Postow;Michael A. Postow

  • Immune Modulation in Cancer with Antibodies

    David B. Page;Michael A. Postow;Margaret K. Callahan;James P. Allison

  • Targeting T Cell Co-receptors for Cancer Therapy

    Margaret K. Callahan;Margaret K. Callahan;Michael A. Postow;Michael A. Postow;Jedd D. Wolchok

  • Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

    Benjamin Weide;Alexander Martens;Jessica C. Hassel;Carola Berking

Frequent Co-Authors

Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Paul B. Chapman
Paul B. Chapman Memorial Sloan Kettering Cancer Center
Katherine S. Panageas
Katherine S. Panageas Memorial Sloan Kettering Cancer Center
Richard D. Carvajal
Richard D. Carvajal Columbia University
F. Stephen Hodi
F. Stephen Hodi Harvard University
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Jianda Yuan
Jianda Yuan MSD (United States)
Georgina V. Long
Georgina V. Long University of Sydney
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re passionate about healthcare but prefer an alternative to medical school, there are many online programs that can launch your career. Pursuing a degree in healthcare administration is a popular choice, and there are online healthcare administration programs designed for those seeking to lead in hospital and clinic settings.

For advanced training, consider the cheapest mha programs online healthcare. These programs are cost-effective and prepare graduates for executive roles within the healthcare industry.

If you’re a nurse aiming for the highest levels of clinical practice, least expensive dnp programs offer a flexible and affordable route to a Doctor of Nursing Practice degree.

For those interested in pharmacology, there are also options for earning your degree online. Check out an online pharmacy degree to open doors in both clinical and research pharmacy roles.

These online pathways provide flexible, affordable options for starting or advancing your career in healthcare—no matter which direction you choose.

Best Scientists Citing Michael A. Postow

Trending Scientists